| Revenue growth | 29.4% CAGR FY21-26 |
|---|---|
| Margins | 19.4% adj. EBITDA margin |
| Order book | Pipeline 17% higher YoY |
| Demand visibility | Strong; sustained 12-15 year drug lifecycles |
| Management confidence | High; pipeline up 17% entering FY27 |
Growth
FY26 revenue grew at 29.4% CAGR (FY21-26); top-20 client revenue tripled since FY21.
Outlook
Targeting multi-billion enterprise status; pipeline entering FY27 is 17% higher than previous year.
Risks
Structural shift in Sales & Marketing centralization; competition from IT scalers and traditional agencies.
Earnings Call filed with NSE, NSE: INDGN. Summary written with AI assistance from the document.
Indegene Ltd: key numbers
- Share price
- ₹608.95
- Market cap
- ₹14,670 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 36.6×Sector 57.8×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 9.92%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Business Update
Indegene Limited hosted its Indegene Digital Summit 2026, focusing on operationalizing AI within life sciences. The event also featured the presentation of the VITAL Awards 2026.
Indegene Merger & Restructuring
Indegene Limited completed the internal merger of its two indirect wholly owned subsidiaries in Germany. This reorganization does not impact Indegene's financial position or operations.
Indegene Earnings Call Transcript: Key Takeaways
Indegene delivered its strongest Q1 growth in four years, yet remains burdened by elevated costs from strategic investments and workforce transformation.
Indegene Investor Presentation: Key Takeaways
Indegene reported Q1'FY27 revenue of ₹10,631M (+39.7% YoY) with an EBITDA margin of 16.9%. The strategy focuses on scaling GenAI-powered solutions and deepening engagement with large pharma.
Indegene Q1 FY27 Results: Net Profit ₹116.2 Cr, Down 0.2% YoY
Indegene Ltd reported revenue from operations of ₹1,063 Cr (+39.7% YoY) and net profit of ₹116.2 Cr (-0.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹116.2 Cr · -0.2% YoY
Indegene Earnings Call: Key Takeaways
Indegene positions as an AI-embedded operating partner for life sciences. Reported FY26 revenue of INR 35.1Bn with 19.4% EBITDA margins and 29.4% CAGR.